NEJM evidenceHumansAdultMaleInfluenzaHuman
Human Challenge Trial of a Nucleoside-Modified Messenger Ribonucleic Acid Influenza Vaccine.
Kelly A Lindert, Alex Mann, Anita Geevarughese, Teresa Hauguel, Sarah Mirza, Melissa Bevan, Kevin Yi, Kayleigh Wolfe, Pascale Nantermet, Kingsley Eze, Pratiksha Dokhe, Agnieszka M Zareba, Emily Gomme, Andrew P Catchpole, Annaliesa S Anderson
Published: 202510.1056/EVIDoa2500087
Abstract
BACKGROUND: Human challenge trials evaluate protection from influenza exposure following vaccination but have not been reported for nucleoside-modified messenger ribonucleic acid (modRNA) influenza vaccines. METHODS: This phase 2a, double-blind trial…
Preview only. Read the full abstract at the source